New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:08 EDTKERX, BBY, WB, MACK, RMTI, SHLD, DB, ARUN, WUBA, AZNOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX WUBA ARUN DB SHLD RMTI MACK WB BBY AZN
News For KERX;WUBA;ARUN;DB;SHLD;RMTI;MACK;WB;BBY;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 21, 2014
12:49 EDTWBAcxiom, Weibo announce partnership
Subscribe for More Information
08:18 EDTDBBasel Committee accelerating work on leverage ratio, FT says
The Basel Committee on Banking Supervision will begin work on the calibration of the leverage ratio, a measure of bank capital seen as less vulnerable to manipulation, sooner than previously planned, which suggests the finished rule could be released as soon as 2015 or 2016, which is ahead of the previous target date of 2017, reported Financial Times, citing comments from the secretary-general of the committee, William Coen. Publicly traded large U.S. banks include Bank of America (BAC), Citigroup (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC). Publicly traded large EU banks include Banco Santander (SAN), Barclays (BCS), Credit Suisse (CS), Deutsche Bank (DB), HSBC (HSBC), ING Groep (ING), Lloyds Banking (LYG), Royal Bank of Scotland (RBS) and UBS (UBS). Reference Link
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:52 EDTDBCiti purchasea Deutsche energy, metals book, Reuters says
Citigroup (C) acquired Deutsche Bank's (DB) energy and metals book, which is the U.S. company's latest expansion effort in commodities trading as some of its competitors look to exit that sector, according to Reuters, citing a source familiar with the matter. Reference Link
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
16:20 EDTSHLDOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTSHLDOptions Update; October 20, 2014
Subscribe for More Information
15:07 EDTSHLDSears Holdings November volatility elevated on sharp rally
Subscribe for More Information
11:10 EDTKERXKeryx management to meet with Oppenheimer
Subscribe for More Information
10:11 EDTSHLDSears comments on rights offering, Primark deal in blog entry
Subscribe for More Information
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:24 EDTSHLDSears board approves rights offering
Sears announced that the company’s board of directors has approved a rights offering allowing its stockholders to purchase up to $625M in aggregate principal amount of 8% senior unsecured notes due 2019 and warrants to purchase shares of its common stock. This rights offering will generate up to an additional $625M in proceeds, if it is fully subscribed and closes as planned, with the proceeds to be used for general corporate purposes. The subscription rights will be distributed to all stockholders of record of the company, and every stockholder will have the right to participate on the same terms in accordance with its pro rata ownership of the company’s common stock, except that holders of the company’s restricted stock that is unvested as of the record date are expected to receive cash awards in lieu of subscription rights. In the rights offering, the company anticipates that holders of its common stock, other than holders of restricted stock that is unvested, will receive subscription rights on a pro rata basis based on shares of common stock held at the close of business on October 30, the record date for the rights offering. Each subscription right will entitle the holder thereof to purchase, at a subscription price equal to the principal amount of each note, one unit, consisting of an 8% senior unsecured note due 2019 in a principal to be determined and a number of warrants equal to that principal amount divided by the strike price for the warrants, with each warrant entitling the holder thereof to purchase one share of the company’s common stock at a strike price of $28.41, the closing market price on October 17. The warrants will be exercisable for a period of five years following the offering. Upon the closing of the rights offering, the components of the units will immediately separate from one another such that the senior unsecured notes and warrants will constitute separate securities and will be transferable separately. The subscription rights will be transferable and are expected to be listed and traded on the NASDAQ. The senior unsecured notes will be transferable but will not be listed for trading on any exchange. The warrants will be transferable, and the company intends to apply to list the warrants for trading on the NASDAQ. Holders of subscription rights who fully exercise all of their subscription rights may also make a request to purchase additional units through the exercise of an over-subscription privilege, although we cannot assure investors that any over-subscriptions will be filled.
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
06:15 EDTSHLDSears files automatic mixed securities shelf
06:07 EDTSHLDSears enters into lease agreement with Primark for seven standalone stores
Sears Holdings announced that it has entered into lease agreements with Primark for seven standalone stores. Sears will continue to have a significant presence in six of these locations with a streamlined store format of up to 100,000 selling square feet at each store. Pursuant to the terms of such agreements and subject to customary conditions, Primark will lease from Sears Holdings a total of approximately 520,000 gross square feet of retail space in mall-based stores located in the Northeastern United States. The space is expected to be delivered to Primark over the next 12 to 18 months.
October 17, 2014
17:31 EDTSHLDESL Partners, affiliates acquire 17.74M common shares of Sears Canada
Subscribe for More Information
15:15 EDTRMTIRockwell Medical volatility elevated
Rockwell Medical November call option implied volatility is at 164, January is at 121, February is at 122; compared to its 26-week average of 76 according to Track Data, suggesting large price movement into a PDUFA Date for Triferic on January 24, 2015.
14:41 EDTKERXKeryx down 4.4% to $15.31, Orange Book cited
Shares of Keryx are lower in afternoon trading after no NCE decision in the Orange Book was updated today, as pointed out by TheStreet's Adam Feuerstein earlier on Twitter.
06:11 EDTWUBA58.com invests $20M for minority stake in Edaijia
58.com announced that it has entered into a definitive agreement to invest $20M for a minority equity stake in Edaijia. Edaijia, which in English means "E-designated driver," is a platform for mobile-based designated driver services in China. The closing of this transaction is subject to customary closing conditions. This transaction is expected to close in late October.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use